Flamingo Therapeutics

Flamingo Therapeutics is a pioneer in tumor RNA-targeted therapy, possessing the most advanced chemical technology. Flamingo Therapeutics has the most cutting-edge antisense RNA-targeted tumor portfolio, with three clinical programs targeting untreatable transcription factors and splicing variants. To support and expand its pipeline, Flamingo Therapeutics has a proprietary discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), capable of addressing LncRNAs—a vast and untapped class of pathogenic targets within the "dark matter" of the human genome. The company was founded in 2020 based on groundbreaking work in the field of oncology lncRNAs through academic partnerships with VIB, KU Leuven, Ghent University, and the University of Michigan.